title: Minimal change disease onset observed after bevacizumab administration.
abstract: This is a report of a patient with minimal change disease (MCD) onset after bevacizumab administration. A 72-year-old man with inoperable Grade 3 astrocytoma was treated with a combination of temozolomide and the vascular endothelial growth factor monoclonal antibody bevacizumab. After two biweekly treatments, he developed nephrotic syndrome. Despite cessation of bevacizumab, his renal function deteriorated and a renal biopsy disclosed MCD. Thereafter, he was started on high-dose oral prednisone and renal function immediately improved. Within weeks, the nephrotic syndrome resolved. Although rare, biologic agents can cause various glomerulopathies that can have important therapeutic implications. MCD should be considered in patients who develop nephrotic syndrome while exposed to antiangiogenic agents.
authors.affiliation: Department of Medicine, Division of Nephrology, Cedars Sinai Medical Center-Office Towers, Los Angeles, CA, USA.
authors.forename: Ramy M
authors.initials: RM
authors.lastname: Hanna
authors.affiliation: Department of Nephrology, Kaiser Permanente, Panorama City, CA, USA.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lopez
authors.affiliation: Surgical Consultative Nephrology, UCLA David Geffen School of Medicine, Director UCLA Stone Center, Los Angeles, CA, USA.
authors.forename: James
authors.initials: J
authors.lastname: Wilson
authors.affiliation: Department of Medicine, Division of Nephrology, Cedars Sinai Medical Center-Office Towers, Los Angeles, CA, USA.
authors.forename: Shrinath
authors.initials: S
authors.lastname: Barathan
authors.affiliation: Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: Arthur H
authors.initials: AH
authors.lastname: Cohen
keywords: angiogenesis; glomerulonephritis; nephrotic syndrome; nephrotoxicity; proteinuria